Alaunos Therapeutics, Inc. (TCRT) · Oct 21, 2026 · Delisting
Regained compliance — $350.0M financing plus $9.0M cash-settlement waiver; Nasdaq confirmation pending
Alaunos’ Nasdaq delisting risk eases after its $350 million financing, but compliance still requires Nasdaq confirmation and shareholder approvals.
Alaunos is transitioning from a largely preclinical company into a pulmonary-hypertension platform after acquiring Velaris, with multiple biologic programs aimed at pulmonary arterial hypertension and related cardiopulmonary diseases. The combined company expects programs to enter clinical development in 2027 and reach proof-of-concept data in 2028, supported by the recently completed financing.
The immediate delisting problem appears contained. Alaunos says the $350.0 million financing, together with a limited waiver covering approximately $9.0 million of preferred stock, puts it back above Nasdaq’s $2.5 million stockholders’ equity requirement (Background; Regained Compliance with the Stockholders’ Equity Requirement). The filing states, “The Company has provided a copy of this Current Report on Form 8-K to the Staff.” 〔0〕
| Item | Filing figure / status |
|---|---|
| Nasdaq minimum stockholders’ equity | $2.5 million (Background) |
| Equity reported in 2025 Form 10-K | $2.153 million (Background) |
| Gross financing proceeds | Approximately $350.0 million (Completion of the Merger and the Financing) |
| Waived cash-settlement exposure | Approximately $9.0 million (Completion of the Merger and the Financing) |
| Nasdaq hearing date | November 10, 2026 (Background) |
This is a company claim, not yet a Nasdaq ruling. The filing says Alaunos believes it has regained compliance, but Nasdaq will continue monitoring the requirement and has not yet confirmed the conclusion. The hearing remains scheduled for November 10, 2026; the company expects it to be cancelled only after Staff confirmation. The filing explicitly warns, “There can be no assurance that Nasdaq will concur with the Company’s determination or as to the timing of any such confirmation.” 〔1〕
The accounting mechanics leave a procedural overhang. Until shareholders approve conversion of the Series B and Series C preferred stock and the related increase in authorized common shares becomes effective, most preferred stock issued in the merger and financing is expected to sit outside permanent stockholders’ equity. The waiver helps because the covered preferred shares can be classified within permanent equity, but the final accounting remains subject to close-process and auditor review (Completion of the Merger and the Financing; Forward-Looking Statements). The September 30, 2026 10-Q also will not show the merger or financing because its balance sheet predates both transactions.
Bottom line: This filing materially reduces the near-term Nasdaq delisting threat and supports the new pulmonary-hypertension buildout, but it does not close the issue by itself. The key remaining step is Nasdaq’s confirmation, with shareholder approvals and final accounting still relevant to keeping compliance intact.
Nasdaq confirmation and November 10 hearing cancellation
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!